Our results demonstrate that the treatment of MDA-MB-435 oestrogen-independent breast cancers with bombesin/GRP antagonists RC-3095 and RC-3940-II significantly decreased the expression of mRNA for VEGF-A, b-FGF and IGF-II, as well as their protein levels. This evidence concerns the gene GRP and breast carcinoma.